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Background: Borna disease virus (BDV) is an evolutionary old RNA virus, which infects brain and blood cells of
humans, their primate ancestors, and other mammals. Human infection has been correlated to mood disorders and
schizophrenia, but the impact of BDV on mental-health still remains controversial due to poor methodological and
cross-national comparability.
Method: This first report from the Middle East aimed to determine BDV infection prevalence in Iranian acute
psychiatric disorder patients and healthy controls through circulating immune complexes (CIC), antibodies (Ab) and
antigen (pAg) in blood plasma using a standardized triple enzyme immune assay (EIA). Samples of 314 subjects
(114 psychiatric cases, 69 blood donors, and 131 healthy controls) were assayed and data analyzed quantitatively
and qualitatively.
Results: CICs revealed a BDV prevalence of one third (29.5%) in healthy Iranian controls (27.5% controls; 33.3%
blood donors). In psychiatric patients CIC prevalence was higher than in controls (40.4%) and significantly
correlating with bipolar patients exhibiting overt clinical symptoms (p = 0.005, OR = 1.65). CIC values were
significantly elevated in bipolar (p = 0.001) and major depressive disorder (p = 0.029) patients as compared to
controls, and in females compared to males (p = 0.031).
Conclusion: This study supports a similarly high prevalence of subclinical human BDV infections in Iran as reported
for central Europe, and provides again an indication for the correlation of BDV infection and mood disorders.
Further studies should address the morbidity risk for healthy carriers and those with elevated CIC levels, along with
gender disparities.
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Borna disease virus (BDV) holds unique features in terms
of its cell biology, molecular properties, preference to old
brain areas, broad host spectrum [1], and unusual bio-
logical age, dating back to more than 40 million years
[2,3]. The outstanding molecular biology of the virus, and
its single
stranded RNA genome leading to the classification [4]
of an own family, Bornaviridae (order Mononegavirales),
has been comprehensively reviewed [5]. BDV had first* Correspondence: 90670@studenti.unimore.it
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article, unless otherwise stated.been recognized as an often deadly pathogen of horses
and sheep [1,6] with a wide spectrum in other domestic
and farm animals. However, BDV’s non-cytolytic proper-
ties, low replication while over-expressing two major
proteins, and evidence of modulating neurotransmitter
networks [7], pointed to a long-term adaption toward
moderate pathogenicity and persistency [1].
Human infection and its putative link to mental disor-
ders, first suggested after detection of antibodies [8], be-
came a key issue inspiring research groups around the
globe. After nucleic acid and antigen could be demon-
strated in white blood cells of psychiatrically diseased pa-
tients [9], such a link was further strengthened by the
finding of specific RNA sequences in post mortem brainsd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Basic data on the population
Groups N Female/Male Mean age + SE Min-Max
Controls 131 83/48 41.08 + 1.009 18-69
Blood donors 69 6/63 29.93 + 1.296 19-58
Mental patients 114 52/62 37.42 + 1.103 17-62
BD* 64 32/32 36.20 + 1.477 17-62
MDD** 12 7/5 43.42 + 3.450 21-57
Schizophrenia 18 3/15 34.56 + 2.689 20-53
Schizoaffective 15 5/10 38.33 + 2.863 22-57
OCD*** 5 5/0 46.20 + 3.967 37-56
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people [11].
The impact of human infection was significantly sup-
ported by the isolation and sequence characterization of
human viruses from psychiatric patients’ blood cells and
brain [12-14], and the recent correlation of neurological
symptoms in humans with BDV infection [15]. The latest
discovery of functional endogenous virus gene pieces inte-
grated in the human and primate ancestor germ lines
strongly argued in favor of a long-term co-evolution of
virus and hosts [2,3,16]. However, a role of BDV, whatso-
ever, in human mental-health remained controversial, des-
pite of predominantly supportive reports [17-24]. This is
mainly due to a great variation in prevalence results largely
caused by methodological disparities, due to different anti-
body and/or RNA techniques, affecting as well cross-
national comparability. In contrast, BDV-specific circulating
immune complexes, the most prevalent infection markers
[25], have shown to be superior to antibody- or RNA- de-
tection. Pilot prevalence studies could demonstrate that the
BDV-CIC enzyme immune assay (EIA) is an easy to per-
form and robust test format, suitable to conducting com-
parable surveys in the general population of different
countries, as well as longitudinal follow-up studies of pa-
tients in clinical cohorts [26-31]. Circulating immune com-
plexes are the result of periods of antigenemia over-
expressing N- and P-proteins, and antibody induction in
the host, reflecting recent and current virus activity. Evi-
dence for a contribution of BDV infection to disease symp-
toms has recently been reviewed [32].
This is the first report from the Middle East, addressing
the prevalence of BDV in the human population in Iran.
The virus in horses has previously been reported by anti-
body studies [33]. Here we explore the prevalence of BDV
markers among Iranian mentally diseased patients, healthy
controls, and blood donors.
Method
Individual subjects
Three hundred and fourteen Iranian subjects, including
114 psychiatric patients, 131 sex and age matched healthy
controls, and 69 blood donors were included in this study.
The association between BDV infection markers in blood
plasma and five DSM IV- categorized psychiatric diseases,
as well as gender and age of the individuals were analyzed.
Basic data are given in Table 1. One hundred and four-
teen acute psychiatric patients, who had been admitted to
local departments of psychiatry in Tehran, were included.
All patients met the Diagnostic and Statistical Manual of
Mental Disorders IV (DSM-IV) -criteria on the basis of
interviews and medical records. They could be divided
into five main groups and different DSM IV codes, includ-
ing 64 bipolar disorder (BD)-, 12 major depressive dis-
order (MDD)-, 18 schizophrenia-, 15 schizoaffective- and5 obsessive compulsive disorder (OCD) patients (Table 2).
Additionally, 69 blood donors and 131 sex- and age
matched, mentally healthy subjects (based on the supervi-
sion of the psychiatrists) were included and regarded as
controls. All individuals were negative for Hepatitis B-
and C-viruses, as well as HIV. The study was approved by
the Ethic Committee of the Neuroscience Research Center
at Shahid Beheshti University of Medical Sciences, and all
patients -or an authorized representative- gave their writ-
ten informed consent for participation. Blood samples of
all individuals were collected prior to any medical treat-
ment and plasma or sera were kept at −20°C.
Enzyme immune assays (EIAs)
The BDV infection markers, circulating immune com-
plexes (CICs), virus antigens (N- and P- protein, N/P-
complexes; abbreviated Ag), and antibodies (Ab), were
assayed using the triple enzyme immune assay (EIA) sys-
tem, as described [25]. According to the double- sandwich
format, two BDV-specific monoclonal antibodies (mAbs),
anti-N mAb (W1) and anti-P mAb (Kfu2), were used to
bind any BDV-N- and P-protein or N/P -heterodimers in
plasma, either circulating antigen bound to virus- specific
host antibodies (CIC- EIA) or free antigen (pAg-EIA).
CICs were visualized through alkaline phosphatase (AP)-
coupled anti-human IgG and substrate, whereas the Ag-
EIA needs a BDV-specific detecting antibody (rabbit
hyper-immune serum) followed by AP phosphatase
coupled anti-rabbit IgG and substrate. The specificity and
sensitivity of the BDV mAbs have been further character-
ized [34]. In particular, epitope mapping has revealed that
both these mAbs are binding to powerful conformational
epitopes on either protein, which are formed through 5
binding sites in case of the anti-N mAb (W1) and 3 bind-
ing sites in case of the anti-P mAb (Kfu2). None of the W1
binding sites are overlapping with P-protein binding do-
mains on the N-protein, confirming that commonly oc-
curring N/P heterodimers are recognized by W1, as well.
Table 2 DSM IV codes, numbers and symptoms of psychiatric patients
Code (N) Symptoms
BD (N=64)
296.02 (2) Single manic episode, moderate
296.03 (4) Single manic episode, severe without psychotic features
296.04 (6) Single manic episode, severe with psychotic features
296.42 (1) Most recent episode manic, moderate
296.43 (5) Most recent episode manic, severe without psychotic features
296.44 (20) Most recent episode manic, severe with psychotic features
296.52 (2) Most recent episode depressed, moderate
296.53 (6) Most recent episode depressed, severe without psychotic features
296.54 (2) Most recent episode depressed, severe with psychotic features
296.62 (2) Most recent episode mixed, moderate
296.63 (11) Most recent episode mixed, severe without psychotic features
296.64 (3) Most recent episode mixed, severe with psychotic features
MDD (12)
296.22 (2) Recurrent, moderate
296.23 (1) Recurrent, severe without psychotic features
296.24 (2) Recurrent, severe with psychotic features
296.32 (3) Single episode, moderate
296.33 (2) Single episode, severe without psychotic features
296.34 (2) Single episode, severe with psychotic features
Schizophrenia (18)
295.01 (3) Disorganized type
295.03 (9) Paranoid type
295.09 (6) Undifferentiated type
Schizoaffective (15)
295.07 (15) Schizoaffective disorder
OCD (5)
300.03 (5) Obsessive compulsive disorder
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overlapping with functionally important sites on N and P-
protein, like NLS (nuclear localization signal) and NES
(nuclear export signal). The extraordinarily high binding
capacities of these mAbs to native N and P proteins have
been determined through affinity-chromatography methods
using N and P protein from the brain of a horse with
Borna disease, resulting in dissociation constants (KD) of
2.31 × 10−9 for W1 and 3.33 × 10−9 for Kfu2. Like for other
antigen assays, recombinant proteins have been used to
determine sensitivity and further confirm specificity. The
detection limit of 1.5-3 ng/ml of purified recombinant N-
protein (rN) has been determined for W1 mAb. Diluting
of rN in CIC-, Ag- and Ab- EIA-negative serum did not
make any difference, confirming specificity. Additionally,
N-protein could be demonstrated in the immune precipi-
tate (IP using W1) of a strongly antigen positive patient’s
plasma by western blot, whereas the IP of an antigen-negative plasma showed nothing but the heavy and light
chain of the mAb [34]. Furthermore, using recombinant
P-protein, either the non-phosphorylated or phosphory-
lated form, revealed that mAb Kfu2 only detects the acti-
vated phosphorylated form. Regarding the antibody assay
we followed the exact protocol given earlier [25]. All three
assays use the basic coating of antibody-stabilized mono-
clonal antibodies (W1 and Kfu2) as a standard immune
module [34].
According to the primary experimental setting, a stan-
dardized cut off value has been specified as a mean of
negative values plus 2 standard deviations, regularly reach-
ing an extinction of < = 0.1 which separates negative and
positive scores. The initial dilutions of the samples were
1:20, 1:2, and 1:100 to allow the same cut off value for test-
ing CICs, free Ag, and Ab, respectively [25]. Results were
visualized through alkaline phosphatase conjugated anti-
bodies and a colorimetric substrate, absorbance measured
Table 3 CIC results against three predictors: sex, age and
diagnosis
Predictors N Pos./Neg. (p %) OR OR Est. CI (95%)
Diagnoses:
Controls 131 36/95 (27.5%) Ref Ref Ref
Blood donors 69 23/46 (33.3%) 1.21 1.029 0.483-2.193
Patients 114 46/68 (40.4%) 1.47 1.088 1.042-3.405
BD 64 29/35 (45.3%) 1.65 2.035 1.072-3.863
MDD 12 6/6 (50.0%) 1.82 2.750 0.820-9.222
Schizophrenia 18 4/14 (22.2%) 0.81 0.632 0.186-2.149
Schizoaffective 15 5/10 (33.3%) 1.21 1.254 0.392-4.014
OCD 5 2/3 (40%) 1.46 2.225 0.343-14.437
Sex:
Male 173 57/116 (32.9%) Ref Ref Ref
Female 141 48/93 (34.0%) 1.03 0.961 0.549-1.682
Age group:
18-25 78 32/46 (41.0%) 1.948 2.962 0.850-10.325
26-35 66 24/42 (36.4%) 1.727 2.422 0.691-8.894
36-45 80 23/57 (28.8%) 1.365 1.597 0.469-5.440
46-55 71 22/49 (31.0%) 1.471 1.830 0.534-6.278
56-65 19 4/15 (21.1%) Ref Ref Ref
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imported to statistical software [25].
Repetition of one third of the sample collection was
performed and essentially gave the same results.
Statistical analysis
All data of the patients and controls were submitted to
parametric and non-parametric statistical analyses. A
comparison of the groups was carried out using independ-
ent T-Tests, ANOVA and Chi square tests. The preva-
lence of BDV infection markers was calculated as based
on the cut off value of 0.1. Subjects were classified accord-
ing to clinical diagnostic, gender and age as independent
variables, as based on the CIC data measured.
The detailed evaluation of CIC tests were based on stan-
dardized scoring of the OD-values of >0.100- 0.300 to
be +, >0.300- 0.600 to be ++, > 0.600 - 1.000 to be +++,
and > 1.000 to be ++++ [25]. Prevalence and odds ratios
(OR) were calculated. Chi square tests were used for an
estimation of statistical differences between the groups.
Furthermore, binary logistic regression for an estimation
of an individual influence of three basic variables, namely




As shown in Table 1, efforts have been made to include
gender and age matched control subjects, but comparabil-
ity could finally not be achieved. The large disparity in
both the female-to-male ratios and age of blood donors
compared to patients considerably accounted for this limi-
tation (gender: chi square = 7.758, p = 005; age: by t test,
p = 0.015). As shown in Table 2, the majority of bipolar
patients (BD) were either manic (59.4%) or in a mixed epi-
sode (25%), whereas only 15.6% experienced a recent de-
pression. Of all patients, only 19.3% (10 BMD, 12 MDD
patients out of 114) presented with a recent depressive
episode.
Circulating immune complexes
Based on CICs we found a mean prevalence of subclin-
ical infection of 29.5% in the healthy Iranian controls,
displaying a slightly higher prevalence in blood donors
(33.3%) as compared to the healthy subject cohort
(27.5%) for whom any mental illness has been excluded.
Gender and age had no significant influence on CIC
prevalence, but psychiatric patients showed significant dif-
ferences compared to the control group (p = 0.036), pre-
senting with a mean CIC prevalence of 40.4%. Particularly,
the patients with bipolar disorder were statistically signifi-
cantly different with reference to CIC prevalence, OR and
OR estimate (OR Est.) (p = 0.014). It is noteworthy that
the CIC prevalence found in patients with mood disorders(BD, MDD, and schizoaffective disorders; N = 91) was
doubling that of schizophrenia patients (44% vs. 22%), a
difference which turned out to be statistically significant
(p = 0.026), as well. The statistical evaluations are given in
Table 3.Free antibody and antigen
Based on the cut-off value of 0.1 [25] valid for all tests
of the triple-EIA system to differentiate the negative
from positive results, free Abs were measured in 7.8%
and 16.7% of the bipolar (BMD) and schizophrenia pa-
tients, respectively, whereas the controls presented with
5.3%. Free Ag was present in 5.6% of the schizophrenic
patients (1 out of 18), vs. 1 % in the controls (2 out of
200). Other patient groups were negative in both tests
(for details see Table 4). The dynamic balance between
CIC formation, antigens, and antibodies accounts for
their relative amounts simultaneously present in a sam-
ple. The cross-sectional design of the study provides an
infection profile only valid at a given time point, thereby
limiting the explanatory power of triple-EIA results.Additional data analysis
According to the cut off values, as shown in Table 5, divid-
ing all data into a negative and positive group and perform-
ing only non-parametric analyses resulted in many data
unavailable for statistical inference. Instead, we used quanti-
tative CIC data from the EIA-reading (after subtraction of
Table 4 Prevalence of free antibodies and antigen
Free antibody Free antigen (N-& P-protein)
Groups Pos./Neg. Prevalence % CI Pos./Neg. Prevalence % CI
Controls 7/124 (5.3%) 1.5-9% 1/130 (0.7%) 0.7-2.3%
Patients 8/106 (7.0%) 2.3-11.7% 1/113 (0.9%) 0-2.6%
BD 5/59 7.8% 1.2-14.4% 0/64 0.0% -
MDD 0/12 0.0% - 0/12 0.0% -
Schizophrenia 3/15 16.7% 0-33.9% 1/17 5.6% 0-16%
Schizoaffective 0/15 0.0% - 0/15 0.0% -
OCD 0/5 0.0% - 0/5 0.0% -
Blood donors 1/68 (1.4%) 0-4.2% 1/68 (1.4%) 0-4.2%
Total 16/298 (5.1%) 2.7-7.5% 3/311 (1%) 0-2%
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analyses.
A noticeable increase in CIC levels of both, the bipolar
disorder (0.147) and the major depressive disorder (0.163)
groups became obvious, being statistically significant
when compared to control subjects. The values for 95%
CI of CICs are illustrated in Figure 1. The CIC levels
within the total population tend to be elevated among
females when compared to males (p = 0.089). Therefore,
the influence of sex on CIC extinction values was also
analyzed in these patient groups (Figure 2). A significant
increase in CIC levels in female patients was recognized
when compared to males (p = 0.031).Table 5 Distribution of categorized CIC results
(neg., +, ++, +++) in subgroups
Subgroups Neg N (%) + ++ +++ Total
Controls 95 (72.5%) 31 (23.7%) 5 (3.8%) 0 131
Blood donors 46 (66.7%) 21 (30.4%) 2 (2.9%) 0 69
Case 68 (59.6%) 36 (31.5%) 8 (7.0%) 2 (1.7%) 114
BD 35 (54.7%) 22 (34.4%) 6 (9.4%) 1 (1.60%) 64
MDD 6 (50.0%) 5 (41.7%) 0 1 (8.30%) 12
Schizophrenia 14 (77.8%) 2 (11.1%) 2 (11.1%) 0 18
Schizoaffective 10 (66.7%) 5 (33.3%) 0 0 15
OCD 3 (60.0%) 2 (40.0%) 0 0 5
Sex
Male 116 (67.1%) 50 (28.9%) 7 (4.0%) 0 173
Female 93 (66.0%) 38 (27.0%) 8 (5.7%) 2 (1.4%) 141
Age groups
18-25 ys 46 (59.0%) 26 (33.3%) 6 (7.7%) 0 78
26-35 ys 42 (63.6%) 20 (30.3%) 4 (6.1%) 0 66
36-45 ys 57 (71.3%) 20 (25.0%) 2 (2.5%) 1 (1.3%) 80
46-55 ys 49 (69.0%) 20 (28.2%) 2 (2.8%) 0 71
56-65 ys 15 (78.9%) 2 (10.5%) 1 (5.3%) 1 (5.3%) 78
OD absorbance is valued as (+): OD absorbance > 0.100 - 0.300, (++): OD
absorbance > 0.300 - 0.600 and (+++): OD absorbance > 0.600.Discussion
This is the first study in Iranian people showing a fairly
high prevalence of Bornavirus infection in healthy individ-
uals including blood donors. The results meet reported
data from Central Europe of about 30% based on the same
infection marker (CIC). The study also supports previous
findings that this neurotropic virus infection is more
prevalent in psychiatric patients than in healthy donors.
According to trends our results are supporting infection
patterns in other countries, like Europe, the Americas
and Asia which are based on specific antibody- and nu-
cleic acid detection [9,10,15,21,35-42], despite of largely
differing prevalence data. Based on measuring BDV re-
leased antigens or antigen-antibody complexes, like
CICs [25,27,29,30], our data showed a much better
agreement.
Studies questioning and reporting the absence of BDV
in both normal and psychiatrically diseased people remain
inconclusive as long as no other cohorts have been inves-
tigated and no other methods have been applied. Among
those are studies of Na et al. [42] and Hornig et al. [43].
The latter group even neglected an own earlier positive
study with contradictory results from the same country
[10]. On the other hand, the existence of a human BDV
strain has recently been independently proven by an
in vitro study in brain cells. Only the human virus was
able to reduce proliferation and enhance apoptosis but
not the animal-derived laboratory strain of BDV [44].
Our study used an established triple EIA which had
been successfully applied to monitor point- and longitu-
dinal prevalence of BDV infection markers in patients
[25,26]. In our hands, these EIAs were found to be easy to
handle and to provide robust and reproducible measure-
ments. It is unfortunate that general acceptance is still
pending. In this study, consecutive sampling of admitted
patients was not possible. Although the data only refer to
cross-sectional sample analysis, BDV markers were signifi-
cantly more prevalent in Iranian patients with mental
diseases than in control subjects. These findings were
Figure 1 Mean and 95% confidence intervals for CIC extinction in the investigated groups. Lower and upper limits of 95% CI in groups
including Control: 0.080-0.095, Schizophrenia: 0.068-0.121, Schizoaffective: 0.056-0.080, Bipolar: 0.125-0.167, MDD: 0.096-0.224, OCD: 0.047-0.134 and
Donor: 0.083-0.105 based on Table 3. *Significant when compared to controls (p = 0.001, ANOVA). **Significant when compared to controls
(p = 0.029, ANOVA). Extinction values refer to 1:20 dilution of plasma in the CIC-ELISA.
Mazaheri-Tehrani et al. Virology Journal 2014, 11:161 Page 6 of 9
http://www.virologyj.com/content/11/1/161similar to data reported from Germany [25,26], Italy [27]
Australia [29], the CSSR [30], China (Xia Liu, Peng Xie, pers.
communication), and Lithuania (Violeta Mockeliūnienė,
Robertas Bunevicius, pers. communication) where the same
test system had been applied.
The presence of CIC with or without antibodies indi-
cates a chronic infection; the presence of Ag, with or with-
out CICs at the same time, a currently active infection.
The finding of free anti-BDV antibody alone (no antigen,
no CICs) is thought to indicate previous exposure to the
agent, but not a current active infection [34]. As shown in
earlier reports CICs represent the major viral marker
explaining the transient disappearance of antibodies and
antigens in blood plasma between activated and dormantFigure 2 Statistical differences between female and male
samples in control and patient groups based on 95% CIC
absorbance (p = 0.031). 131 control samples (83 female and 48
male) and 114 patient samples (52 female and 62 male) were
calculated by a parametric t-student test.phases of virus infection, and by this providing also a clue
for the true number of silently infected carriers in a
healthy cohort or population [25,26,34].
Iranian psychiatric patients show a clearly elevated
CIC sero-prevalence (40.4%) compared to healthy con-
trols (27.5%). It is of special interest that 33.3% of sam-
ples from blood donations were silent virus carriers, a
finding confirming Australian [29] and German pilot re-
ports [17,26], thus being quite in contrast to an earlier
report [45]. Transfusion issues relating to BDV infection
are still awaiting further clarification [46].
BD, MDD and OCD patients presented with infection
rates of 45.3%, 50.0% and 40.0%, respectively. However,
significance levels were only reached in BD patients.
This might be due to the small sample size, but in para-
metric data analysis, comparing OD values of absorb-
ance (extinction), high levels of CICs in sera from BD
and MDD patients were also significant.
In contrast to other reports [47,48], we found a rela-
tively high sero-prevalence of free Ab and Ag in schizo-
phrenic patients (16.7% and 5.6%, respectively) which is
consistent with a relatively low CIC sero-prevalence
among those individuals (22.2%, see Table 2). In addition
to schizophrenic patients, only BD patients showed free
antibodies in their sera (7.8%). This implies that BDV
antibodies are usually bound in immune complexes and
are therefore becoming transiently absent in the blood
stream.
It is of considerable interest that the CIC sero-
prevalence adversely correlated with the corresponding
age groups (linear regression done using age as continu-
ous data, R = −0.116, p = 0.042), which means that the
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limit includes only adults 18 years and older. This leaves
the question whether younger people are either more
prone to BDV infection or their immune response is more
prominent. It supports a recent finding that young chil-
dren (from 4–6 months to 3 years of age) had even much
higher infection rates, although this pilot study warrants
further investigations [28,34], In addition, it has to be fur-
ther examined whether and to which extent vertical trans-
mission of BDV in the pregnant horse [49], mouse [50]
and human [28] contributes to higher infection rates at
young age. In this regard, high prevalence of BDV in the
normal population, lifelong persistence of the virus in in-
fected subjects (patients or healthy people), and the so
far undisclosed function of endogenized BDV genome
stretches [2,3,16], might reflect further risk factors war-
ranting urgent future investigations.
Interestingly, significant differences between female and
male patients could be measured for the first time
(Figure 2. middle, p = 0.031), showing a prevalence of
CICs in 42.3% of females, and 38.7% in males. In favor of
these findings, two female patients, belonging to the BD
and MDD groups, had high CIC titers with levels above
0.6 (+++) (Table 5). The sero-prevalence among healthy
controls, however, reached only 25.3% in females and
31.3% in males.
Such sex-related specific differences according to, titers
and prevalence of an antibody response to foreign anti-
gens, infectious agents, or even auto antigens are known
from the literature [51-55]. Females usually exhibit a
stronger humoral immune response, as especially known
after vaccination and infection with microbial agents. In
fact, estrogens exert stimulatory effects on B cell prolifera-
tion and serum IgG levels, whereas testosterone may sup-
press B cell function [56,57].
In conclusion, Iranian people seem to fit into the pattern
of BDV infections, so far reported worldwide [5]. More-
over, the study benefits from using prevalent infection
markers and a highly specific and effective test system
[26,34]. The study confirms evidence for a high infection
prevalence, similar to Central Europe, in one third of
healthy Iranian subjects, contrasting elevated levels in pa-
tients with mood disorders. In view of millions of people
worldwide suffering from depression and the huge related
health care costs [58], this study points again to integrat-
ing BDV infection surveillance in psychiatric research [26]
rather than to continue in underplaying its impact.
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